Iron: The redox-active center of oxidative stress in Alzheimer disease

Neurochemical Research

Volumn 32, Issue 10, 2007, Pages 1640-1645

  Castellani, Rudy J ^a   Moreira, Paula I ^b   Liu, Gang ^c   Dobson, Jon ^d   Perry, George ^e,f   Smith, Mark A ^f   Zhu, Xiongwei ^f  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d KEELE UNIVERSITY   (United Kingdom)

^e University of San Antonio   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Alzheimer disease; Chelation; Neurodegeneration; Oxidative stress; Redox active iron

Indexed keywords

IRON; METAL; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; CHELATION THERAPY; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE MARKER; HUMAN; IRON OVERLOAD; IRON TRANSPORT; NEUROFIBRILLARY TANGLE; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SENILE PLAQUE;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; HUMANS; IRON; NEUROFIBRILLARY TANGLES; OXIDATION-REDUCTION; OXIDATIVE STRESS; SENILE PLAQUES;

EID: 34548744723     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-007-9360-7     Document Type: Review

References (82)

1. Marlatt MW, Webber KM, Moreira PI et al (2005) Therapeutic opportunities in Alzheimer disease: one for all or all for one? Curr Med Chem 12:1137-1147
2. Castellani RJ, Lee HG, Zhu X et al (2006) Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathol (Berl) 111:503-509
3. Woods J, Snape M, Smith MA (2007) The cell cycle hypothesis of Alzheimer's disease: suggestions for drug development. Biochim Biophys Acta 1772:503-508
4. Rouault TA (2001) Systemic iron metabolism: a review and implications for brain iron metabolism. Pediatr Neurol 25:130-137
5. Rouault TA (2001) Iron on the brain. Nat Genet 28:299-300
6. Roy CN, Andrews NC (2001) Recent advances in disorders of iron metabolism: mutations, mechanisms and modifiers. Hum Mol Genet 10:2181-2186
7. Moos T (1996) Immunohistochemical localization of intraneuronal transferrin receptor immunoreactivity in the adult mouse central nervous system. J Comp Neurol 375:675-692
8. Kawamata T, Tooyama I, Yamada T et al (1993) Lactotransferrin immunocytochemistry in Alzheimer and normal human brain. Am J Pathol 142:1574-1585
9. Leveugle B, Spik G, Perl DP et al (1994) The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis. Brain Res 650:20-31
10. Patel BN, Dunn RJ, David S (2000) Alternative RNA splicing generates a glycosylphosphatidylinositol-anchored form of ceruloplasmin in mammalian brain. J Biol Chem 275:4305-4310
11. Klomp LW, Gitlin JD (1996) Expression of the ceruloplasmin gene in the human retina and brain: implications for a pathogenic model in aceruloplasminemia. Hum Mol Genet 5:1989-1996
12. Crowe A, Morgan EH (1992) Iron and transferrin uptake by brain and cerebrospinal fluid in the rat. Brain Res 592:8-16
13. Bowman BH, Jansen L, Yang F et al (1995) Discovery of a brain promoter from the human transferrin gene and its utilization for development of transgenic mice that express human apolipoprotein E alleles. Proc Natl Acad Sci USA 92:12115-12119
14. Lieu PT, Heiskala M, Peterson PA et al (2001) The roles of iron in health and disease. Mol Aspects Med 22:1-87
15. Double KL, Zecca L, Costi P et al (2000) Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins. J Neurochem 75:2583-2589
16. Hentze MW, Kuhn LC (1996) Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci USA 93:8175-8182
17. Connor JR, Menzies SL, Burdo JR et al (2001) Iron and iron management proteins in neurobiology. Pediatr Neurol 25:118-129
18. Calabrese V, Scapagnini G, Ravagna A et al (2002) Regional distribution of heme oxygenase, HSP70, and glutathione in brain: relevance for endogenous oxidant/antioxidant balance and stress tolerance. J Neurosci Res 68:65-75
19. Maines MD (2000) The heme oxygenase system and its functions in the brain. Cell Mol Biol (Noisy-le-grand) 46:573-585
20. Marcus DL, Thomas C, Rodriguez C et al (1998) Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp Neurol 150:40-44
21. Sayre LM, Zelasko DA, Harris PL et al (1997) 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 68:2092-2097
22. Smith MA, Richey Harris PL, Sayre LM et al (1997) Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 17:2653-2657
23. Smith MA, Taneda S, Richey PL et al (1994) Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci USA 91:5710-5714
24. Smith MA, Perry G, Richey PL et al (1996) Oxidative damage in Alzheimer's. Nature 382:120-121
25. Smith MA, Harris PL, Sayre LM et al (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 94:9866-9868
26. Nunomura A, Perry G, Pappolla MA et al (1999) RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci 19:1959-1964
27. Zhou Y, Richardson JS, Mombourquette MJ et al (1995) Free radical formation in autopsy samples of Alzheimer and control cortex. Neurosci Lett 195:89-92
28. Martins RN, Harper CG, Stokes GB et al (1986) Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer's disease may reflect oxidative stress. J Neurochem 46:1042-1045
29. Pappolla MA, Omar RA, Kim KS et al (1992) Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease. Am J Pathol 140:621-628
30. Lovell MA, Robertson JD, Teesdale WJ et al (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158:47-52
31. Hall ED, Oostveen JA, Dunn E et al (1995) Increased amyloid protein precursor and apolipoprotein E immunoreactivity in the selectively vulnerable hippocampus following transient forebrain ischemia in gerbils. Exp Neurol 135:17-27
32. Shi J, Perry G, Smith MA et al (2000) Vascular abnormalities: the insidious pathogenesis of Alzheimer's disease. Neurobiol Aging 21:357-361
33. Abe K, St George-Hyslop PH, Tanzi RE et al (1991) Induction of amyloid precursor protein mRNA after heat shock in cultured human lymphoblastoid cells. Neurosci Lett 125:169-171
34. Jendroska K, Poewe W, Daniel SE et al (1995) Ischemic stress induces deposition of amyloid beta immunoreactivity in human brain. Acta Neuropathol (Berl) 90:461-466
35. Murakami N, Yamaki T, Iwamoto Y et al (1998) Experimental brain injury induces expression of amyloid precursor protein, which may be related to neuronal loss in the hippocampus. J Neurotrauma 15:993-1003
36. Shi J, Xiang Y, Simpkins JW (1997) Hypoglycemia enhances the expression of mRNA encoding beta-amyloid precursor protein in rat primary cortical astroglial cells. Brain Res 772:247-251
37. Mattson MP, Pedersen WA (1998) Effects of amyloid precursor protein derivatives and oxidative stress on basal forebrain cholinergic systems in Alzheimer's disease. Int J Dev Neurosci 16:737-753
38. Gabuzda D, Busciglio J, Chen LB et al (1994) Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem 269:13623-13628
39. Misonou H, Morishima-Kawashima M, Ihara Y (2000) Oxidative stress induces intracellular accumulation of amyloid beta-protein (Abeta) in human neuroblastoma cells. Biochemistry (Mosc) 39:6951-6959
40. Olivieri G, Hess C, Savaskan E et al (2001) Melatonin protects SHSY5Y neuroblastoma cells from cobalt-induced oxidative stress, neurotoxicity and increased beta-amyloid secretion. J Pineal Res 31:320-325
41. Frederikse PH, Garland D, Zigler JS Jr et al (1996) Oxidative stress increases production of beta-amyloid precursor protein and beta-amyloid (Abeta) in mammalian lenses, and Abeta has toxic effects on lens epithelial cells. J Biol Chem 271:10169-10174
42. Paola D, Domenicotti C, Nitti M et al (2000) Oxidative stress induces increase in intracellular amyloid beta-protein production and selective activation of betaI and betaII PKCs in NT2 cells. Biochem Biophys Res Commun 268:642-646
43. Atwood CS, Scarpa RC, Huang X et al (2000) Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J Neurochem 75:1219-1233
44. Atwood CS, Moir RD, Huang X et al (1998) Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 273:12817-12826
45. Curtain CC, Ali F, Volitakis I et al (2001) Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem 276:20466-20473
46. Huang X, Atwood CS, Hartshorn MA et al (1999) The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry (Mosc) 38:7609-7616
47. Dikalov SI, Vitek MP, Maples KR et al (1999) Amyloid beta peptides do not form peptide-derived free radicals spontaneously, but can enhance metal-catalyzed oxidation of hydroxylamines to nitroxides. J Biol Chem 274:9392-9399
48. Perry G, Nunomura A, Raina AK et al (2000) Amyloid-beta junkies. Lancet 355:757
49. Smith MA, Joseph JA, Perry G (2000) Arson. Tracking the culprit in Alzheimer's disease. Ann NY Acad Sci 924:35-38
50. Joseph J, Shukitt-Hale B, Denisova NA et al (2001) Copernicus revisited: amyloid beta in Alzheimer's disease. Neurobiol Aging 22:131-146
51. Rottkamp CA, Raina AK, Zhu X et al (2001) Redox-active iron mediates amyloid-beta toxicity. Free Radic Biol Med 30:447-450
52. Rottkamp CA, Atwood CS, Joseph JA et al (2002) The state versus amyloid-beta: the trial of the most wanted criminal in Alzheimer disease. Peptides 23:1333-1341
53. Cullen KM (1997) Perivascular astrocytes within Alzheimer's disease plaques. Neuroreport 8:1961-1966
54. Dunn CJ (1991) Cytokines as mediators of chronic inflammatory disease. In: Kimball ES (ed) Cytokines and inflammation. CRC, Boca Raton, FL, pp 1-33
55. Yoshida T, Tanaka M, Sotomatsu A et al (1998) Activated microglia cause iron-dependent lipid peroxidation in the presence of ferritin. Neuroreport 9:1929-1933
56. Cadman ED, Witte DG, Lee CM (1994) Regulation of the release of interleukin-6 from human astrocytoma cells. J Neurochem 63:980-987
57. Sayre LM, Perry G, Harris PL et al (2000) In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem 74:270-279
58. Shan X, Tashiro H, Lin CL (2003) The identification and characterization of oxidized RNAs in Alzheimer's disease. J Neurosci 23:4913-4921
59. Honda K, Smith MA, Zhu X et al (2005) Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J Biol Chem 280:20978-20986
60. Hirai K, Aliev G, Nunomura A et al (2001) Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21:3017-3023
61. Mikhaylova A, Davidson M, Toastmann H et al (2005) Detection, identification and mapping of iron anomalies in brain tissue using X-ray absorption spectroscopy. J R Soc Interface/R Soc 2:33-37
62. Collingwood JF, Mikhaylova A, Davidson M et al (2005) In situ characterization and mapping of iron compounds in Alzheimer's disease tissue. J Alzheimers Dis 7:267-272
63. Collingwood JF, Mikhaylova A, Davidson MR et al (2005) High-resolution x-ray absorption spectroscopy studies of metal compounds in neurodegenerative brain tissue. J Phys: Conf Ser 17:54-60
64. Dobson J, Grassi P (1996) Magnetic properties of human hippocampal tissue-evaluation of artefact and contamination sources. Brain Res Bull 39:255-259
65. Schultheiss-Grassi PP, Wessiken R, Dobson J (1999) TEM investigations of biogenic magnetite extracted from the human hippocampus. Biochim Biophys Acta 1426:212-216
66. Kirschvink JL, Kobayashi-Kirschvink A, Woodford BJ (1992) Magnetite biomineralization in the human brain. Proc Natl Acad Sci USA 89:7683-7687
67. Hautot D, Pankhurst QA, Khan N et al (2003) Preliminary evaluation of nanoscale biogenic magnetite in Alzheimer's disease brain tissue. Proceedings 270(Suppl 1):S62-S64
68. Dobson J (2001) Nanoscale biogenic iron oxides and neurodegenerative disease. FEBS Lett 496:1-5
69. Dobson J (2004) Magnetic iron compounds in neurological disorders. Ann NY Acad Sci 1012:183-192
70. Timmel CR, Till U, Brocklehurst B et al (1998) Effects of weak magnetic fields on free radical recombination reactions. Mol Phys 95:71-89
71. Scaiano JC, Monahan S, Renaud J (1997) Dramatic effect of magnetite particles on the dynamics of photogenerated free radicals. Photochem Photobiol 65:759-762
72. Bush AI (2002) Metal complexing agents as therapies for Alzheimer's disease. Neurobiol Aging 23:1031-1038
73. Shachar DB, Kahana N, Kampel V et al (2004) Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 46:254-263
74. Bartzokis G, Tishler TA, Lu PH et al (2007) Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol Aging 28:414-423
75. Jack CR Jr, Wengenack TM, Reyes DA et al (2005) In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. J Neurosci 25:10041-10048
76. Ritchie CW, Bush AI, Mackinnon A et al (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60:1685-1691
77. McLachlan DR, Kruck TP, Lukiw WJ et al (1991) Would decreased aluminum ingestion reduce the incidence of Alzheimer's disease? CMAJ 145:793-804
78. Liu G, Garrett MR, Men P et al (2005) Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochim Biophys Acta 1741:246-252
79. Smith MA, Atwood CS, Joseph JA et al (2002) Predicting the failure of amyloid-beta vaccine. Lancet 359:1864-1865
80. Lee HG, Casadesus G, Zhu X et al (2004) Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. Ann NY Acad Sci 1019:1-4
81. Kaur D, Yantiri F, Rajagopalan S et al (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37:899-909
82. Cherny RA, Atwood CS, Xilinas ME et al (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30:665-676